Today's Breaking News
- Genentech Provides Update on Phase III Studies of Etrolizumab in People With Moderately to Severely Active Ulcerative Colitis
- FDA Approves New Opioid for Intravenous Use in Hospitals, Other Controlled Clinical Settings
- FDA Approves Genentech’s Evrysdi (risdiplam) for Treatment of Spinal Muscular Atrophy (SMA) in Adults and Children 2 Months and Older
Latest R&D and Business News
- Vaxart Announces IND Filed for COVID-19 Vaccine
- GeneCure Biotechnologies launches first-in-human therapeutic vaccine to treat Covid-19 patients
- BIOQUAL Announces Publication in The New England Journal of Medicine of Non-Human Primate Preclinical Viral Challenge Study of an mRNA Vaccine Against COVID-19 (mRNA-1273)
- Gilead Submits New Drug Application to U.S. Food and Drug Administration for Veklury® (Remdesivir) for the Treatment of COVID-19
- Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection
- Verastem Oncology Signs Definitive Agreement to Sell COPIKTRA® (duvelisib) Rights to Secura Bio to Focus on Development of VS-6766 and Defactinib in KRAS Mutant Solid Tumors
- AnaptysBio Reports Top-Line Data From Interim Analysis of ECLIPSE Phase 2 Clinical Trial of Etokimab in Chronic Rhinosinusitis with Nasal Polyps
- Pieris and Lilly Enter Into a Clinical Trial Collaboration to Evaluate Combination of PRS-343 With Ramucirumab and Paclitaxel in Gastric Cancer
- Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) Demonstrates Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma
- U.S. Food and Drug Administration Approves Lampit® (nifurtimox) for the Treatment of Chagas Disease in Children
- Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan: Takeda
- FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review